Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC). He succeeds co-founder Scott Glenn, who will serve as adviser and remain on the board. The company also said it is planning to raise a series C next quarter followed by an IPO next year.

Autoimmune disease company Step Pharma S.A.S. (Paris, France) hired Andrew Parker as CEO, succeeding founding CEO Geoffroy de Ribains. Parker was EVP and CSO at Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL)...